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Colchicine Induced Multiple Drug Resistance In C-6 Glioma (80pp.)
Director; Charles L. Eyer, Ph.D.

Multiple drug resistance (MDR) is a common problem that occurs with repeated exposure
to some anticancer drugs. MDR is produced by increased synthesis of an active transport
system that lowers intracellular levels of a variety of anticancer drugs. Colchicine has
been shown to induce MDR in several cancer cell lines. Cancer treatment with taxol has
been complicated by the the induction of MDR with repeated exposure. C6 glioma
represents a well characterized model of the most common human brain tumor. We
investigated the ability of colchicine to induce resistance to taxol in this cell line. Our
research focused on three objectives: a), to determine whether drug resistance to taxol
can be induced by colchicine in a C6 glioma cell line. b). to determine colchicineinduced changes in protein content, stress response, and key enzyme levels (heme
oxygenase (HO), glutamine synthetase (GS), and cyclic nucleotide phosphohydrolase
(CNP). c). to determine whether drug resistance can be reversed by verapamil — a known
inhibitor of the multiple drug resistance transport system.
Drug resistance was verified by comparing the EC50 values of both the control and
colchicine treated cells upon exposure to increasing concentrations of taxol. Colchicine
applied for a 24 hour period at a concentration of 480 ng/ml induced drug resistance to
taxol in the C-6 glioma cell line, as evidenced by a greater than 14 fold increase in taxol's
EC50. The resistant strain also exhibited is an increase in the amount of protein per cell;
and increased HO activities. Drug resistance was reversed by verapamil. These studies
show that colchicine has induced resistance to taxol and that the resistance appears to be
related to the induction of the multiple drug resistance receptor.
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INTRODUCTION

a. Drug Resistance:
Oncologists agree that one of the important unsolved problems in cancer
treatment is drug resistance. This includes both intrinsic resistance at the time of initial
chemotherapy and acquired drug resistance. In general terms, acquired drug resistance
may result from alterations in host drug metabolism, from spread of tumor cells to sites
poorly accessible to chemotherapy ("sanctuary sites"), and/or from biochemical changes
at the cellular or subcellular level (Perez et. al, 1993). (TABLE 1.)

Table 1. Mechanisms Of Resistance To Chemotherapy

Host factors
Altered pharmacokinetics
Decreased drug absorption-activation
Enhanced drug excretion-degradation
Altered binding-transport proteins
Host-tumor factors
Metastasis of cells to "sanctuary sites"
Cellular factors
Decreased drug accumulation
Decreased influx or increased efflux
Altered cellular metabolism
Decreased activation or increase degradation
Cytoplasmic-nuclear inactivation
Glutathione / Metallothioneins / ? proteins
DNA repair / tolerance to DNA damage
Altered cellular target

To investigate the basis of drug resistance, drug-resistant cell lines have been
isolated by exposing various cancer cell lines to increasing amounts of chemotherapeutic
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antibiotics, for example, adriamycin; the resistant cells that are isolated are frequently not
only resistant to adriamycin but may be cross-resistant to most naturally occurring
antibiotics. The simultaneous resistance to many different structurally unrelated drugs is
called multiple drug resistance (MDR). MDR includes resistance to many natural
products isolated from plants (e.g. Taxol, colchicine) and microorganisms. Multiple drug
resistance does not appear to extend to agents synthesized in the laboratory such as
cisplatin, cytosine arabinoside, cyclophosphamide, and methotrexate (Gottesman and
Pastan, 1988). (TABLE 2).

Table 2. Drugs In The Multiple Drug Resistance Group
ANTICANCER DRUGS

OTHER DRUGS

ACTINOMYCIN D
DAUNOMYCIN
DOXORUBICIN
ETOPOSIDE (VP-16)
MITOXANTRONE
TAXOL
VINBLASTINE
TENIPOSIDE (VM-26)
VINCRISTINE

COLCHICINE
EMETINE
ETHIDIUM BROMIDE
GRAMICIDIN D
MITHRAMYCIN
PUROMYCIN
VALINOMYCIN

The drugs in the MDR group do not share a common mechanism of action; some
affect microtubules and some inhibit DNA, RNA, or protein synthesis. The biochemical
basis of this type of resistance came from studies showing that MDR cells accumulated
less drug (Dano, 1973; Ling and Thompson, 1974). Drug entry appeared to be normal,
but the cells had acquired the capacity to pump out the drugs (Fojo, et. al, 1985). There
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was no good precedent for a single transport protein that could pump such structurally
diverse drugs out of cells.
One common feature of the drugs in the MDR group is that they are moderately
soluble in both water and lipid (amphipathic). The solution to how a single transport
protein or proteins could pump out such structurally diverse drugs from cells came when
the gene responsible for MDR (MDR 1-also known as p-glycoprotein) was isolated from a
very highly drug-resistant cell line derived from a cervical carcinoma (Robinson, et. al.,
1986; Chen, et. al, 1986).
With the isolation of a full-length cDNA for the MDRl gene, it was possible to
transfer the MDRl cDNA into drug-sensitive cells and confer resistance. Because the
introduction of a single gene in a drug-sensitive cell led to resistance to adriamycin,
vinblastine, actinomycin D, taxol, and colchicine, it was concluded that a single
membrane protein must be able to transport a wide variety of drugs that are structurally
dissimilar (Pastan, et. al, 1988).
The first step in drug chemotherapy is the transport of the drug from an aqueous
extracellular environment into the lipid environment of the plasma membrane. From here
the drugs can diffuse into the cytoplasm and nucleus where their cytotoxic action occurs.
The drugs may encounter the p-glycoprotein transporter to pump them back out of the
cell (Comwell, et. al, 1986, 1987). Recent data support the idea that the pump
recognizes and expels drugs directly from the plasma membrane (Raviv, et. al, 1990).
Many drugs that have no antineoplastic activity are also substrates for the multiple
drug transporter and can competitively block the transport of the cytotoxic drugs (Pastan
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and Gottesman, 1991). When present in excess, these inhibitors overcome MDR by
preventing the multiple drug transporter from removing adriamycin, vinblastine,
colchicine or other cytotoxic agents from resistant cells (TABLE 3).

Table 3. Drugs Currently In Trial To Reverse Multiple Drug
Resistance
Calcium channel blockers
R- & L- Verapamil
Cyclosporine A and its
analogs
Hydrophobic Cephalosporins

Phenothiazines
Quinidine
& Quinine
Reserpine
Yohimbine

Dalton and coworkers studied multiple drug resistance expression in multiple
myeloma and showed that patients who no longer responded to a regimen including
vincristine, adriamycin, and dexamethasone did become responsive when treated with
verapamil. Some patients developed a transient remission (Meister, 1985).
A ^^P-cDNA probe to measure MDRl RNA levels and antibodies was used to
determine the function and precise cellular location of the multiple drug transporter
(Thiebaut, et. ai, 1987; Fojo, et. ai, 1987). The transporter has been detected in the
liver, kidney, large and small intestines, pancreas, brain, testes, and adrenal cortex. Since
the substrates for the multiple drug transporter are natural products found in plants and
microorganisms, researchers believe the transporter evolved as a protective mechanism to
prevent the entry of toxic compounds from the intestine or to remove toxic compounds
via the bile and urine if they were absorbed. In addition, the transporter prevents
compounds from entering the brain (perhaps as part of the blood-brain barrier) and the
testis (Pastan and Gottesman, 1991).
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Colchicine is an alkaloid that can be obtained from two members of the lily
family: autumn crocus and glory lily (Ferguson, F.C., 1952). Colchicine binds to tubulin
and thus prevents its polymerization into microtubules. This antimitotic property disrupts
the spindle apparatus that separates chromosomes during metaphase (Wallace, S.L., et.
al, 1970). Colchicine has been used to induce drug resistance and to investigate the
properties of multiple drug resistance in human ovarian cancer cells and in transfected
mouse cell cultures (Ling, V., et. al, 1974; Podda, et. al, 1992).
Taxol, a taxane alkaloid, is the major active species of extracts derived from the
bark of the Pacific yew, Taxus brevifolia (Wani, M.C., et. al, 1971). The mechanism of
action of taxol has been demonstrated to be unique, constituting tubulin polymerization
and stabilization of microtubules rather than the depolymerization reported for the classic
antimicrotubule agents vincristine and colchicine (Schiff, P.B.,, et. al, 1979). Cross
resistance of taxol with other natural products has been demonstrated in vitro (Gupta,
R.,1985).
Verapamil is one of several drugs currently in clinical trials to reverse the multiple
drug resistance associated with cancer chemotherapy (Pastan, L, and Gottesman, M.,
1991). The 1-stereoisomer, is used clinically as a calcium channel blocker. Verapamil
appears to inhibit the efflux of toxic chemotherapeutic drugs by acting as a substrate of Pglycoprotein, thereby, allowing drugs like vincristine, colchicine, and taxol to remain
within the cell and exert their cytotoxic action (Racker, E., et. al, 1986).

b. Heat shock proteins / stress response:
A major question in molecular biology is how cells cope with rapid changes in
their environment, such as exposure to elevated temperatures (heat shock), heavy metals.
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toxins, oxidants, drugs, bacteria, and viruses. It has become clear that all living
organisms share a common molecular response that includes a dramatic change in the
pattern of gene expression and the elevated synthesis of a family of heat shock or stressinduced proteins (Morimoto, et. al, 1990; Lindquist, et. al, 1988).

i) Background and Signiflcance
Immediately after a sudden increase in temperature, all cells—from the simplest
bacterium to the most highly differentiated neuron—increase production of a certain class
of molecules that buffer them from harm. When biologists first observed that
phenomenon 30 years ago in Drosophila cells (Tissieres, et. al., 1974), they called it the
heat shock response. Subsequent studies revealed that the same response takes place
when cells are subjected to a wide variety of other environmental assaults, including toxic
metals, alcohols (Neuhaus-Steinmetz, et. al, 1993), and many metabolic poisons
(Schlesinger, 1990—TABLE 4).

Table 4. Inducers Of Stress Response Family Members

Environmental

Pathophysiologic

-Heat
-Heavy metals

-Microbial
infections
-Tissue trauma

-Organics

-Genetic lesions

Other
-Cell cycle
-Embryonic
development
-Cell differentiation

-Oxidants
-Hormone stimulation
-Microbial growth
The ability to respond to environmental challenges is a fundamental requirement
for the survival of all living organisms. This is consistent with the observation that one of
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the mechanisms by which cells respond to such signals (the heat shock/stress response),
and many of the proteins that are synthesized as components of this response are highly
conserved among widely divergent organisms. For example, the major heat shock
protein, Hsp 70, has about 50% of its sequence conserved between E. coli and human,
and some domains are 96% similar. (Surdon, 1986 and Lindquist, 1986).
The Hsp 70 proteins (heat shock protein—molecular weight approximately 70,000
dalton) are needed for import of several proteins into eukaryotic cell organelles. Other
Hsp 70 family members act inside these organelles, as does a protein that belongs to a
different family of heat shock proteins, the Hsp 60 or GroEL group. For import into the
organelle, it is proposed that Hsp 70 unfolds the partially folded polypeptide so that it can
be translocated through a membrane pore (Hightower, 1980). Consistent with this role
are data showing that Hsp 70 like protein can bind to and, in the presence of ATP,
dissociate protein complexes. Among these are clathrin-coated vesicles, a X
bacteriophage DNA replication complex, nucleolar proteins that have become insoluble
as a result of heat shock and immunoglobin heavy chains formed in the absence of light
chains.
In most stressed cells, the newly made Hsp 70 localizes in the nucleus and the
nucleolus where it is tightly complexed in an insoluble form that is partially solubilized
by ATP. The nucleolus is the site of ribosome assembly and is unusually thermal
sensitive. It is suggested that Hsp 70 binds to proteins that are incompletely folded in the
preribosome assembly unit and protects them from irreversible denaturation.
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Another family of heat shock proteins, Hsp 60's, also form complexes with
polypeptides and has ATPase activity. In contrast to the postulated unfolding and
disassembly role of most Hsp 70's; Hsp 60's participate in the folding and assembly of
polypeptides. Based on this property, they have been referred to as chaperonins
(Hemingsen, et. al, 1988). In the eukaryote, the Hsp 60's are localized in cytoplasmic
organelles such as mitochondria and chloroplasts.
A third heat shock protein family is the Hsp 90 (approx. 90,000 daltons) group. In
the eukaryote Hsp 90 is abundant in normal cells, is highly phosphorylated on serines and
threonines, and is localized in the cytoplasmic compartment of the cell. A small fraction
of it translocates to the nucleus after heat shock. Like the Hsp families noted above, Hsp
90 complexes with a variety of normal cellular proteins (TABLE 5).

The most thoroughly studied are the glucocorticoid receptors that are maintained in
inactive conformation bound to Hsp 90 until activated by the hormones. Several kinases
are transiently complexed with this heat shock protein, most notable are the tyrosine
kinases encoded by oncogenes. Another kinase, one that phosphorylates the eukaryote
translation-initiation factor eIF-2a subunit, is activated by Hsp 90. The cytoskeletal
proteins, actin and tubulin, are associated noncovalently with Hsp 90. Hsp 90's may also
function as a chaperonin. Microfilaments and microtubules (which are affected by both
colchicine and taxol) are not unusually sensitive to stress although a prolonged and severe
heat shock modifies both structures. In contrast, the intermediate filament network is
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very thermal sensitive (Parcell and Sauer, 1989). It is believed that the Hsp 90 protects
and aids in the recovery of these cytoskeletal systems.

Table 5. Proteins Complexed With HSP
HSP 70 Family
-clathrin-coated
vesicles
-prepro a factor
-nucleolar
proteins
-IgG Heavy chain
-p53 tumor
antigen
-DNA replication
initiation
-complex
(phage,plasmid)
-calmodulin
-SV40 T-antigen
-microtubules
(P-intemexin)

HSP 90 Family
-glucocorticoid
receptor
-tyrosine kinases
-eIF-2a kinase
-yeast protein
kinase C
-tubulin
-actin

Hsp 60 (GroEL)
Family
-À, phage collars
-ribulose-p2
carboxylase/
oxygenase heavy
chain
-cytochrome c
-Fl-ATPase
-temperaturesensitive mutants

In addition to improper polypeptide folding, heat shock leads to a plethora of
changes that are dependent on both the intensity of the stress and on the cell system.
These include effects on macromolecular synthesis, on levels of cations, on states of
protein phosphorylation, on metabolic pathways, and on cytoskeleton networks (Parcell,
et. al., 1989).

ii) Interaction between MDR and the stress response
Chin, et. al, (1986) reported that exposure of a renal adenocarcinoma cell line to
heat shock or sodium arsenite increased MDRl mRNA levels (Chin, K-V., et. al, 1990).
In a separate study in which a hepatocarcinoma cell line HepG2 was treated with sodium
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arsenite about a twofold increase of MDRl mRNA was observed (Kioka, et. al, 1992).
Heat shock at 45°C for 10 minutes also increased the level of MDRl mRNA. Heat shock
at 42°C for 1-2 hours, also had a marginal effect.
Thermotolerance, resistance to oxidative stress, and induction of stress proteins
were examined in a panel of 10 human tumor cell lines (Steels, et. al, 1992). This
research showed that a heat shock of 42.5°C for 30 min. was sufficient to induce
tolerance to a subsequent heat stress of 43.5°C for 3 hr. in four human cell lines. The
initial heat shock itself was not lethal (100% survival). The heat stress alone resulted in
20-40% survival in four of the cell lines. Induction of Hsp 70 was evident in HeLa and
two melanoma cell lines two (2) hours after heat shock. However, this treatment did not
induce other Hsp's (Hsp 28, Hsp 90).

iii) Heme oxygenase
Heme oxygenase is an enzyme which catalyzes the oxidative conversion of heme
(iron-protoporphyrin-K Fe-heme) to the linear tetrapyrrole biliverdin by insertion of two
oxygen atoms into the tetrapyrrole ring adjacent to the alpha-methene bridge (Trakshel,
et. al, 1988) (FIGURE 1).
The oxygen atoms utilized in this reaction are derived from two separate
molecules of oxygen. An additional molecule of oxygen is used to convert the alphamethene carbon to carbon monoxide. During this process the central iron atom is
released. The microsomal origin of the enzyme was first described by Tenhunen, et. al,
in 1968. The substrate and kinetic characteristics of the enzyme in microsomes were
defined thereafter (Maines, 1984).
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Heme oxygenase has been resolved into two isozymes, designated HO-1 and HO2, appearing in several tissues including brain (Cruse and Maines, 1988). HO-1 and HO2 appear to be products of different genes (Trakshel and Maines, 1989). They differ
immunologically and physically and show species diversity (Shibahara, et. al, 1987).
Similarities have been observed with respect to cofactor requirements for activity,
sensitivity to inhibitors, as well as substrate used, i.e., hematin, hematoheme, and
cytochrome c. Both forms of the enzyme require NADPH-cytochrome c (P-450)
reductase, NADPH, or NADH, and O2 for activity. The activity of both forms can be
inhibited by potassium cyanide, sodium nitrite, and carbon monoxide. Both forms cleave
the tetrapyrrole molecule exclusively at the alpha meso bridge to form biliverdin IX
alpha-isomer. Both forms utilize hematin and hematoheme as substrates but not intact
cytochrome c. HO-1 is also a heat shock protein (Dwyer, et. al, 1989). The rat HO gene
contains a functional heat shock element consensus sequence in its promoter region
(Mitani, et. al, 1989). It is inducible by a variety of stressful conditions including
hyprerthermia (Keyse and Tyrell, 1987), ultraviolet radiation, hydrogen peroxide (H2O2),
sodium arsenite, (Keyse & Tyrell, 1989; Taketani, et. al, 1989), cadmium (Taketani, et.
al, 1989), and hemin (Yoshida, et. al, 1988, Stocker, 1990). It has been postulated that
since heme oxygenase is a sensitive indicator of oxidative stress in some cells (Fligiel, et.
al, 1984), it can possibly protect cells by elevating intracellular bilirubin, which is an
antioxidant (Stocker, et. al, 1987

12
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Figure 1. Metabolic Fate Of Heme

C. C-6 Glioma Cells As The Model System
Gliomas are prominent nervous system tumors that have received considerable
experimental scrutiny in the disciplines of oncology and molecular biology (James, et. al,
1989; Kinzler, et. al, 1987). The C6 Glioma, which is chemically induced from rat brain,
has generally been designated as an astrocytoma (Benda, et. al, 1968; Benda, et. al,
1971; & Embree, et. al, 1971). Research has shown that C-6 Glioma cells
transdifferentiate or phenotypically change as a function of cell passage. With time, these
cells develop more astroglial and less oligodendroglial characteristics, as measured by
their decreased expression of 2',3'-cyclic nucleotide 3'-phosphohydrolase
(CNP)(E.C.3.1.4.1) and increased glutamine synthetase (GS)(E.C.6.3.1.2) activity
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(Parker, et. al, 1981; Parker, 1989). GS is used as a characteristic enzyme marker for
astroglial cells (Norenberg and Martinez-Hernandez, 1979) and CNP as an enzyme
marker for oligodendrocytes (Poduslo and Norton, 1972).
Rat C-6 glioma cells were chosen for this study to investigate glioma cell
properties and function because of the consistency of expression, degree of
characterization, and the dependability of culturing conditions of the C-6 cell line
(Pfeiffer, et. al, 1977; Vemadakis, et. al., 1986).

D.Intracellular Markers
i) Glutamine synthetase
Studies have shown that the glutamine synthesis (GS) antigen in the adult brain is
exclusively localized to astrocytes (Norenberg and Martinez-Hernandez, 1979). These
findings were consistent with those demonstrating high glutamine synthetase activity in
astrocytes cultures (Schousboe, et. al, 1977). This cytosolic enzyme is distributed
approximately equally in both fibrous and protoplasmic astrocytes. A number of
experimental workers emphasize the key role of astrocytes in ammonia detoxification and
in the metabolism of the putative neurotransmitters y-amino-butyric acid and glutamic
acid ( Henn & Hamberger, 1971; Norenberg, 1976; Schrier & Thompson, 1974)
(FIGURE 2 ).
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Glutamine synthetase is considered as a reliable astrocyte marker for establishing
cellular identification in tissue culture, developmental studies, studies involving
neoplastic transformation and differentiation, and as a means of monitoring astrocytes in
pathological states (Norenberg and Martenez-Hemandez, 1979).

it) 2',3'Cyclic nucleotide,3'-phosphohydrolase (CNP)
(EC.3.1.4.1)
Cyclic nucleotide phosphohydrolase (CNP) is an enzyme or a series of related
enzymes capable of hydrolyzing ribonucleoside 2',3'-cyclic phosphates. The enzyme is
not capable of hydrolyzing intemucleotide bonds nor is it capable of cleaving the more
well known 3',5'-cyclic phosphates. (FIGURE 3). The cellular location of the enzyme
has been used as an important tool for neurochemists (Zanetta, et. al, 1972). Cyclic
nucleotide phosphohydrolase was first shown to be present at high concentrations in
myelin rich neural fractions and thus became a marker for myelin. The reason for this
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localization became evident later as CNP was found to be localized in high
concentrations in the oligodendrogiial cell plasma membrane. Therefore, CNP has
become an important marker for oligodendroglia (Prohaska, et. al, 1973).
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e. Specific Objectives
Whether a correlation exits between heat shock or the stress response and drug
resistance in the rat C-6 Glioma cell line has not been reported. We have investigated the
heat shock / stress response and drug resistance in the C-6 Glioma cell line with the
following objectives:
(I). To determine whether a drug resistant cell line can be induced with colchicine.
(II). To characterize differences in the protein content, stress response, and key
enzyme levels in the parent (control) and colchicine treated cells.
(III). To determine whether the drug resistance seen with colchicine pretreatment
can be reversed by verapamil.

MATERIALS AND METHODS
I. CELL CULTURE:
C6 glioma cells were started from a locally maintained cell line. Cells were
recultured approximately every 10 days. Passages used for these studies were taken
from passages 70 to 81. Cells were maintained in either Coming (or equivalent) 75
cm^ flasks or multiple well culture flasks. Usual culture conditions involved growing
cells in D-MeM/F-12 medium fortified with 10% fetal bovine serum, penicillin (100
ug/ml), streptomycin (100 ug/ml), and fungizone (250 ug/ml). The medium was
changed every 2-3 days, while being maintained at 37°C in a humidified atmosphere
of5%C02.

IL REAGENTS AND DRUGS:
Chemicals, reagents, and drugs were obtained from the indicated sources. Rat
C-6 Glial tumor cells (American Type Culture Collection Rockville, Md).
Acrylamide, N,N,-methylenebis acrylamide (BIS), Trizma base, tetrasodium
ethylenediamine tetraacetic acid (EDTA), N,N,N',N'-tetramethylene amine
(TEMED), Ammonium persulfate [(NH4)2S208], Sigma 7-9 tris, b-mercaptoethanol
(2ME), glycine, glycerol, bromphenol blue, SDS molecular weight markers (14,00070,000), SDS molecular weight markers (30,000-200,000), Deferroxamine mesylate.
Bovine serum albumin, Hemin chloride-bovine, b-Nicotinamide adenine dinucleotide
phosphate (b-NADPH), Biliverdin dihydrochloride,Protein, total-micro-Brilliant blue
G, Bovine serum albumin standards, Tris-HCL (buffer). Tris maleate (buffer).
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monophosphate (2'-AMP), Alkaline phosphatase. Ammonium molybdate, Imidazol
hydrochloride (buffer), 1-glutamine, hydroxylamine, Adenosine 5' diphosphate
(ADP), g-glutamyl-hydroxymate (L-glutamic acid- g-monohydroxymate). Colchicine,
Verapamil, (Sigma Chemical Co.; St. Louis, Mo.). Potassium chloride (KCl),
Sodium bicarbonate (NaHCOs), Sodium phosphate monobasic (NaH2P04) Potassium
phosphate monobasic (KH2PO4), Potassium phosphate dibasic (K2HPO4), Sodium
hydroxide (NaOH), Hydrochloric acid (HCL), Magnesium chloride (MgClz 4H2O),
Ferric chloride (FeCl]), Sodium chloride (NaCl), Sulfuric acid (H2SO4), Sodium
Arsenate (Na2HAs04), Sucrose, Manganese chloride (Mncl2 8H2O), Trichloroacetic
acid (TCA), Isopropyl alcohol (Isopropanol), Methyl alcohol (methanol), Benzene,
Isobutyl alcohol (Isobutanol), Glacial acetic acid, (Fisher Chemical, Fair Lawn, NJ.).
Trypan blue stain (0.4%), Earle's balanced salt solution (BBSS), Dulbecco's modified
Eagle's medium (D-MEM/F-12), Penicillin-Streptomycin 5000 units/ml. Fungizone
(Amphotericin B 250 ug/ml & Sodium deoxycholate 205 ug/ml). Trypsin (2.5%),
(Gibco Laboratories, Life Technologies, Inc.). Taxol (Calbiochem, Lajolla, Ca.),
Sodium Dodecyl Sulfate (BHD British House, Poole BH15 ITD, England).

III. EXPERIMENTAL PROTOCOL:
a. Development of a Drug Resistant Cell Line
Rat C-6 Glioma cell cultures were used throughout this research project. Cells
were grown and maintained in Coming (or equivalent) 75 cm^ flasks and six-well
culture plates. The cells were grown in D-MEM/F-12 medium fortified with 10%
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fetal bovine serum, Penicillin (100 ug/ml). Streptomycin (100 ug/ml), and Fungizone
(250 ug/ml Amphotericin B & 205 ug/ml Sodium deoxycholate). The medium was
changed every 2-3 days while being maintained at 37°C in a humidified atmosphere
of 5 % % .
Sets of six 6-well plates were incubated over a 7-10 day period. When
microscopic examination had shown that confluent growth had been achieved, the
cells were subjected to varying concentrations (250-2000 ng/ml) of colchicine
dissolved in D-MEM/F-12 medium for a twenty four hour period. Each 6-well plate
contained one well that was used as a solvent control. At the end of the 24 hour
treatment period, the D-MEM/F-12 media was aspirated and the cells were harvested
by adding 1.0 ml isotonic 0.25% trypsin. The trypsinized cells were then pipetted into
separate prelabeled tubes containing 2-3 volumes of ice cold D-MEM/F-12 medium.
The response of the cells to colchicine was then assessed by microscopically counting
the cells (as described in Appendix B-Trypan Blue Cell Counting Procedure). The
EC50 of colchicine (the dose in which there is a 50% inhibition of growth of the cells)
was determined by using the Pcnonlin software program. Correlation coefficient (Rvalues) were 0.9 or better for EC50 determination.
b. Assessment of Drug Resistance
Six-well culture plates were exposed to the EC50 concentration of colchicine
for 24 hours. Drug exposure was then terminated and the cells were grown to
confluence in the standard D-MEM/F-12 medium. Drug resistance was assessed by
subjecting the cells to varying concentrations (100-5000 ng/ml) of taxol. Cells were
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harvested and counted as described previously. Taxol EC50 values were determined
for both the colchicine treated cells and the control (PNT) cells.
c. Induction of Stress
Confluent cultures of the colchicine treated and parent (control) cells were
subjected to heat stress by incubating them at 42° C for 30 minutes. 24 hours later the
cultures were harvested and counted. Cells were then prepared for protein and
enzyme determinations (see part 4).
d. Assays Procedures
The details of the analytical procedures are described in Appendix B.
i) Cell Counts:
Two hundred microliters (200 ul) of the previously trypsinized cell suspension
was pipetted into a tube containing 300 ul of 0.85% saline and 500 ul Trypan blue. A
sufficient volume of the Trypan blue cell suspension was transferred to a
hemacytometer. All of the cells in each of the four comer and center grids were
counted for each sample. The average number of cells obtained was multiplied by 5
to correct for the dilution factor. To obtain the number of cells per milliliter in the
original solution, the corrected number was multiplied by 10"^ (Bauer H, et.al., 1975).
ii) Protein Analysis:
A microprotein technique (Sigma cat.#610-A) that employs Brilliant Blue G
was used (Bradford, 1976). The Brilliant Blue G dye (Coomassie Blue) reacts almost
immediately with protein to form a blue colored protein dye complex. The amount of
color produced is proportional to the protein concentration. In the assay procedure,
the C-6 Glioma cell homogenates along with protein standards were first solublized
by heating at 80°C for 10 minutes in 0.05N NaOH. After neutralization with 1.2 IN
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HCL, the blanks, standards, and samples were reacted with protein dye solution. The
absorbance (O.D.) of each was measured at 595 nm. The amount of protein in each
sample was calculated from the slope of the regressed line in which the absorbance
(O.D.) was plotted against the concentration mg/ml) of the protein standards.
iii) Heme Oxvsenase Activity
The enzymatic procedure used was the spectrophotometric method to measure
the formation of bilirubin (Tenhunen et. al, 1968) as modified by Lincoln et.al.
(1988). The method relies on the use of the endoplasmic reticular fraction of the C-6
Glioma cell homogenate and the addition of previously isolated rat liver cytosolic
fraction as a source of biliverdin reductase (see Heme Oxygenase Assay-Appendix
B). Hemin was then added to the reaction mixture. The presence of heme oxygenase
in the C-6 Glioma cell homogenates, oxidatively catalyzes the conversion of hemin to
bilirubin. Subsequently, the presence of biliverdin reductase and ^-Nicotinamide
adenine dinucleotide phosphate (p-NADPH) in the reaction mixture reduced
biliverdin to bilirubin. The conversion of hemin via the two step process to bilirubin
was measured spectrophotometrically at 453nm. The heme oxygenase activity
(umol/min) was determined from a standard curve prepared with bilirubin standards.
The heme oxygenase activity was expressed as pmol/min/mg of protein.
iv) Glutamine Synthetase Activity (GS):
GS was assayed by the colorimetric method of Meister (1985). In this
procedure, the enzymatic activity in the C-6 Glioma cell homogenates and prepared
standards were followed by the use of the y-glutamyl transfer reaction in which
glutamine synthetase catalyzes the conversion of L-glutamine in the presence of
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hydroxylamine, catalytic quantities of Adenosine 5' diphosphate, and inorganic
arsenic to y-glutamylhydroxymate; which gives a characteristic color reaction upon
addition of ferric chloride. The absorbance (O.D.) for each of the standards and
samples was measured spectrophotometrically at 555nm. The yglutamylhydroxymate activity (umol/min) was determined from a standard curve
prepared with y-glutamylhydroxymate. The y-glutamyl- hydroxymate activity was
expressed as nmol/min/mg protein.
v) 2 '3'-Cyclic Nucleotide 3'Phosphohydolase (CNP) Activity:
The procedure used was the spectrophotometric method to measure the
formation of 2'-adenosine monophosphate(Prohaska et. al, 1973). Aliquots of C-6
Glioma cell homogenates and standards were incubated with 2%3'-cyclic adenosine
monophosphate to yield 2'-adenosine monophosphate. Alkaline phosphatase was
added to cleave inorganic phosphate from the 2'-adenosine monophosphate. The
inorganic phosphate was reacted with ammonium molybdate and then the complex
was extracted in isobutahol/benzene (1:1). The yellow color produced in the organic
layer was then measured spectrophotometrically at 410nm. The 2%3'-cyclic
nucleotide phosphohydrolase activity (umol/min) was determined from a standard
curve prepared with of 2'-adenosine monophosphate standards. The CNP activity
was expressed as umol/min/mg of protein.

vi) Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
(SDS-PAGE)
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The SDS-PAGE procedure used utilized the tris-glycine discontinuous system
(Laemmli, 1970) as modified by Dr. Ralph Judd (1987,1988). C-6 Glioma cell
homogenates, including the parent strain, the colchicine treated strain, and cultures
exposed to heat shock, were subjected to SDS-PAGE ( as described in Appendix B)
along with commercially prepared molecular weight protein markers. After fixing in
50% methanol; 7% acetic acid: 43% distilled water, the proteins were visualized with
Coomassie Brilliant Blue R. The technique was used for this study to visually assess
the presence of heat shock proteins including Hsp 32 (heme oxygenase), Hsp 70, and
Hsp 90.

e. The Effect Of Verapamil On Drug Resistance
Four twenty-four well culture plates containing the colchicine treated strain
were treated with varying concentrations (1 uM, 5 uM, and 10 uM in D-MEM/F12
medium) of verapamil for 24 hours. At the end of 24 hours, the colchicine treated
cells (including appropriate controls) was subjected to varying concentrations (1002000 ng/ml) of taxol for 24 hours. Finally, the cells were trypsinized, harvested and
then placed in Trypan blue stain. Cells were then counted microscopically to
determine the effects of taxol on cell growth.

f. Statistics
Student t-tests were used to determine significant differences between the
parent (control) cells and the colchicine treated cells. ANOVA and Scheffe's tests
were used to determine significant differences among multiple treatment means (both
stressed and unstressed), p < .05 = significant difference. PCnonlin was used to
determine EC50 values for taxol.

RESULTS

OBJECTIVE I:. To determine whether a drug resistant cell line can be induced
with colchicine.
Throughout this study, the Trypan Blue exclusion staining technique was used
to determine cell viability. While colchicine decreased cell counts, no indication of
cell death nor cellular debris was detected.
Figure 4 shows the effect of varying concentrations of colchicine on cell
counts. Cell counts decreased from 87.3 ± 3.3 % of control at a concentration of 250
ng/ml to 33.6 ± 3.0 % of control at a concentration of 2000 ng/ml. A PCnonlin
statistical program was used to calculate the ECsoof colchicine (480 ng/ml).
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Figure 4. Effects of colchicine on cell counts All values are mean ± s.e.m.
Each data point represents n =6. Cell counts decrease from 87.3 ± 3.0% of
control at 250 ng/ml to 33.6 ± 3.0% of control at a concentration of 2000
ng/ml.
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An additional effect of colchicine was noted in a small study (N = 2),
comparing the total number of cells counted at 24 hour intervals in the control cells
(PNT) and the colchicine treated cells (CLT). Results shown in Figure 5 indicate that
cell counts, after exposure to colchicine for 24 hours, decreased for approximately 72
hours. At ninety six (96) hours, cell counts in the colchicine treated cells is
approximately equal to that of the control cells (PNT).
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Figure 5. Effect of colchicine pretreatment on cell counts. PNT = control cells;
CLT = colchicine treated cells. Each point represents the mean value, n = 2. At
96 hours both the control and colchicine treated cell counts were at
approximately 9.0 x 10^ cells per flask.

Taxol was much less effective in cells previously exposed to colchicine
(Fig.6). The control cells shows less resistance to taxol (decrease in the mean cell
counts as a % of control) than the colchicine treated cells. The taxol concentration

ranged from 0-2000 ng/ml in the control cells and ranged from 0-5000 ng/ml in the
colchicine treated cells. Using a PCnonlin statistical program, the taxol EC50 in the
parent (control) cells was determined to be 82.0 ± 23.5 ng/ml. The taxol EC50 in the
colchicine treated cells was determined to be 1490.3 ± 157.7 ng/ml. Values are
expressed as mean + 95% confidence interval.
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Figure 6. Effect of taxol on cell counts. PNT = control cells (EC50 = 82 ±
23.5 ng/ml). CLT = colchicine treated (EC50 = 1490.3 ± 157.7 ng/ml). %
control values = mean ± s.e.m. EC50 values = mean ± 95% confidence
interval.
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Objective H: To characterize differences in the protein content, stress response,
and key enzyme levels in the parent (control) and colchicine treated cells.

a. Heat shock proteins:
Cell cultures from both treatments, stressed (heat shocked) and unstressed,
were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE). Visual examination of Coomassie stained gels (pages 34-37) showed the
presence of several bands with similar molecular weights to the heat shock proteins—
Hsp 28, Hsp 60, Hsp 70, Hsp 90. A band having a molecular weight of
approximately 32 kDa (Hsp 32 -heme oxygenase) was apparent on all gels.
However, a perceptible increase in the well known heat shock protein Hsp 70 was not
observed on either the stressed or the unstressed cultures. Densitometric scans were
performed which compared the stressed colchicine treated cells(CLT + HS) to a
known, commercially prepared, protein standard molecular weight marker mixture.
The densitometric scan on the gel from the colchicine treated cells showed the
presence of several peaks having similar retention times to the peaks seen on the scan
of the molecular weight marker mixture. However, induction of stress (increase in
Hsp 70 or Hsp 32) was not observed on the scan from the colchicine treated cells,
(pages 38-39).

b. Protein content:
Measurement of the amount of protein per cell indicated a significantly higher
concentration in the colchicine treated cells (3.73 ± .15 x 10 ^ ug per cell). The
amount of protein in the control cells was 3.2 ± .20 xlO'^ ug per cell (Fig. 7).
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c. Heme oxygenase (HO):
Colchicine pretreatment increased HO activity (58 + 3 pmol/min/mg protein)
(Fig 8). Heme oxygenase activity in the unstressed control cells was determined to be
(33 ± 7 pmol/min/mg protein). Heat shock treatment significantly increased heme
oxygenase activity in the control cells (60 ± 6 pmol/min/mg protein). HO activity
appeared to increase when the CLT cells was heat shocked (53 ± 7 pmol/min/mg
protein), however no significant difference was detectable (p = .059).

I

I PNT rarai

CLT
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^

4 h

Figure 7. Effect of colchicine on cellular protein content (ug protein x 10"^)
per cell. Cells harvested 24 hours after colchicine removed from medium.
Values are mean ± s.e.m. * = significant difference (p < 0.05). PNT and
CLT are defined in Fig. 5.
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PNT+HS

CLT+HS

Figure 8. Effect of colchicine and heat shock on heme oxygenase activity.
PNT and CLT are defined in Fig. 5. HS = heat shock. Bars not sharing a
common letter are significantly different ( p< 0.05). All values are mean ±
s.e.m. n = 6.
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d. Glutamine synthetase (GS):

PNT+HS

CLT+HS

Figure 9. Effect of colchicine and heat shock on glutamine synthetase
activity. No significant difference in GS activity was noted between the
PNT, PNT + HS, and the CLT treated cells.PNT, CLT and HS are defined
in Figs. 5 & 8. See Fig. 8 for explanation of statistics.

Glutamine synthetase in the unstressed control cells (PNT) was determined to
be 2.0 ± 0.2 nmol/min/mg protein . GS activity in the stressed control cells (PNT +
HS) was 2.0 nmol/min/mg protein. In the unstressed colchicine treated cells (CLT)
no significant increase in GS activity was noted (2.17 ± 0.17 nmol/min/mg protein).
A significant increase (p < .05) in GS activity was determined in the stressed
colchicine treated cells (CLT + HS)(2.83 ± 0.17 nmol/min/mg protein). No statistical
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significance was noted between the control cells, the stressed control cells, or the
colchicine treated cells (Fig. 9).

e. Cyclic Nucleotide Phosphohydrolase (CNP):
Colchicine did not significantly increase CNP activity (Fig. 10). No significant
difference was noted between the unstressed control cells (PNT) and the
unstressed colchicine treated cells (CLT)(0.218 ± 0.015 umol/min/mg protein).
The CNP activity in the stressed colchicine cells were significantly higher than
either the stressed or unstressed control cells. Heat stress did not significantly
increase the CNP activity in the colchicine treated cells (0.249 ± 0.006
umol/min/mg protein vs. 0.218 ± 0.015 umol/min/mg protein in CLT), although
the former value was significantly higher than values obtained with the control
cells.

PNT+HS

CLT+HS

Figure 10. Effect of colchicine and heat shock on CNP activity. Only the
stressed colchicine treated cells showed increased CNP activity.See Fig. 8 for
details of legends and statistics.
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Objective III: To determine whether the drug resistance seen in the colchicine
treated strain can be reversed by verapamil.

The colchicine treated cells were pretreated with varying concentrations of
verapamil (1 uM, 5 uM, & 10 uM). A significant increase in cell counts was seen in
the colchicine treated cells in the presence of 10 uM of verapamil (Fig. 11).
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Figure 11. Effect of verapamil on cell counts in the CLT cells. Cells exposed
to 1,5, or 10 uM verapamil for 24 hours prior to counting. * = significantly
different from other concentrations (p < 0.05). Values are mean ± s.e.m. n =6.
Verapamil, at a 10 uM concentration, was effective in decreasing colchicine
resistance to taxol (Fig. 12). Figure 13 compares the effects of verapamil on taxol
ECso values in the colchicine treated cells to the original EC50 data shown in Figure 6.
The taxol EC50 of passage 81 was 9103 ± 2088 ng/ml; at 1 uM verapamil
pretreatment the
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Figure 12. Effect of verapamil (1, 5, and 10 uM) on the CLT strain's response
to taxol. 10 uM verapamil significantly decreases the colchicine resistance to
taxol.See Fig. 8 for details of statistics.
taxol EC50 was 676 ± 240 ng/ml; at 5 uM verapamil pretreatment the taxol EC50 was
439 ± 56 ng/ml; and at 10 uM verapamil pretreatment the taxol EC50 was 72 ± 50
ng/ml. By comparison, the taxol EC50 in the control cells was 82 ± 23 ng/ml; and the
taxol EC50 in the colchicine treated cells was 1490 ± 158 ng/ml. Verapamil produced
a concentration-dependent reversal in the colchicine-induced drug resistance to taxol.
This reversal was essentially complete in presence of 10 uM verapamil.
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CNTL
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Figure 13. Effects of verapamil on the response of CLT to taxol. EC50's for
Passage 81 were determined following exposure to the indicated concentration of
verapamil. CNTL = CLT cells not exposed to verapamil. CLT and PNT are
defined in Fig. 5. Bars represent mean ±95 % confidence interval. Values for
Passage 70, both PNT and CLT, are shown on the right side of the graph.
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Fig. 14. Separation of proteins after heat shock (42°C for
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Lane 1, SDS-Page Molecular Weight

marker standard I; lanes 2-7, parent strains I-VI; lane 8,
SDS- Page molecular weight marker standard II; lane 9, SDSPage molecular weight marker standard III.
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Concentration of proteins in the SDS-PAGE molecular marker
standard were at approximately 1 microgram per microliter.
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DISCUSSION
Objective I: To determine whether drug resistant cell line can be induced with
colchicine.
The data shown in Figure 4 was used to determine the concentration of
colchicine to be used for further studies on drug resistance. The calculated colchicine
EC50 value of 480 ng/ml was selected to induce drug resistance in this C-6 glioma
model. The concentration of colchicine chosen initially inhibited cell growth during
the 24 hour exposure. Seventy-two (72) hours after removal of the colchicine, the C6 glioma cell growth had returned to a level (9.0 x 10^ cells per 75 cm^ flask) which
was not significantly different from the control (9.14 x 10^ cells per 75 cm^ flask)
(Fig. 5). In addition, the EC50 concentration did not appear to be lethal to the glioma
cells.
Podda, et. al. (1992) reported that colchicine kills MDR-negative cells.
However, they also did not see cell death in cell cultures which were continuously
exposed to colchicine for 3 days. Kane and Gottesman, (1993), reported that in
colonies continuously exposed to colchicine for 7-14 days, drug sensitive cells were
not killed by colchicine but were prevented from dividing.
Previous studies have shown colchicine to be a MDR inducible drug (Podda,
et. al, 1992). In the presence of colchicine, cells that are not multiple drug resistant
become multinucleated and cell division is inhibited. Cells that express MDR
become resistant to the drug. By increasing the selective pressure (colchicine
concentration) on those cells, they express progressively more MDR gene product to
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1988) or by enrichment for cells in a population that already express high levels of
MDR (Kane, et. al, 1989).
Evidence that colchicine treatment induced drug resistance in C-6 glioma is
strongly indicated by the shift of the taxol concentration response curves (Fig. 6) and
the 15-fold increase in EC50 . Our study is apparently the only study known that has
established taxol EC50 values in C-6 glioma. This level of resistance is higher than
that seen by other investigators in different cell lines. Kelland, et. al, (1992)
compared the cytotoxic properties of taxol in nine human ovarian carcinoma cell
lines. They reported that exposure of the ovarian carcinoma cell lines to taxol for two
(2) hours showed a 3-9 fold increase in taxol EC50; whereas, a continuous 96-hour
exposure revealed a 2-6 fold increase. In comparing our study to Kelland's, it is
apparent that the taxol EC50 concentrations may vary significantly from cell line to
cell line. Differences may best be explained by the studies of Pastan, et. a/., (1991) in
which several fold differences may be seen based on the degree of expression of pglycoprotein. Tumors derived from colon, kidney, liver, and pancreas usually have
high levels of p-glycoprotein (MDRl), a reflection of the high level in the normal
cells from which the tumor arose. Expression of the MDRl gene is sometimes high
in leukemias, lymphomas, and some other cancers derived from tissues that do not
normally express the gene. Increased MDRl expression has been observed in drugresistant leukemias, myelomas, ovarian cancer, breast cancers, sarcomas, and
neuroblastomas (Goldstein, et. al, 1989), and has often been predictive of
unresponsiveness to treatment.
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Our results indicate that we have developed drug resistant C-6 glioma cells.
Noting that the control and CLT cells differ in their response to taxol, our next step
then was to characterize changes in certain key intracellular components.

Objective II: To characterize differences in the protein content, stress response,
and key enzyme levels in the control and colchicine treated cells.

a. Heat Shock Proteins:
Our results, using SDS-PAGE, showed the presence of several electrophoretic
bands, on Coomassie stained gels, having similar molecular weights to the heat shock
proteins—Hsp 28, Hsp 60, Hsp 70, and Hasp 90. Commercially prepared protein
standard molecular weight marker mixtures were analyzed in conjunction with the
stressed and unstressed parent and colchicine treated strains. A band having a
molecular weight of approximately 32 kDa (possibly Hsp 32—heme oxygenase) was
apparent on all gels. Visual examination of the gels was insufficient in determining
clear differences in protein electrophoretic patterns between the control cells and the
colchicine treated cells. A densitometric scan on the gel from the stressed colchicine
treated cells showed the presence of several peaks having similar retention times to
the peaks seen on the scan of the molecular weight marker mixture. The induction of
stress, as characterized by increases in peak areas at retention times similar to
compounds having molecular weights at 32 kDA or 70 kDA, was not observed (pages

38-39).
At the present time, two isoforms of heme oxygenase exist; HO-1 and HO-2 —
both forms having nearly identical molecular weights. HO-1 apparently is the only
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inducible form (Maines, et. al, 1985). Taketani, et. al, (1989) were not able to
distinguish the isoforms of heme oxygenase in rat liver fractions using gel
electrophoresis without [^^S] methionine labeling of the proteins and immunoblotting.
Trakshel and Maines (1989) used antibodies to characterize differences in rabbit HO1 and HO-2. Neither, the [^^S] Methionine labeling of proteins nor antibodies to HO1 or HO-2 techniques were available in our lab at the time this study was carried out.

b. Protein content
One of the criteria used in this study to characterize differences between the
control and colchicine treated cells was the amount of protein per cell. Our study
showed a significant increase in the amount of protein per cell in the colchicine
treated cells (3.73 ± 0.15 x 10"^ ug per cell) versus the amount of protein found in the
control cells (figure 7). The amount of protein per cell in our control cells (PNT)
(3.20 ± 0.15 X 10 ^ ug per cell) was almost double the level reported by Parker, et. al,
(1980) in a 2-B clone C-6 glioma cell line (1.86 ± 0.13 x 10^ ug per cell). The
difference in the two protein levels may be due to the fact that our glioma cell line
was from the American Culture Collection. This line may express a higher level of
protein than the 2-B clone.

c. Heme Oxygenase (HO):
Dwyer, et. al, (1992) characterized heme oxygenase as a stress protein that is
inducible by heat shock (stress). In our cell cultures (passage #70) harvested 24 hours
after heat stress, a heat shock response was clearly demonstrated by the increase in
heme oxygenase activity. Basal HO activity in the untreated control cells (PNT) was
33 ±7 pmol/min/mg protein (Fig. 8). Heat shock (stress) increased HO activity
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approximately 2-fold in both the control (PNT + HS) and the colchicine treated cells
(CLT + HS). In addition, the unstressed colchicine treated cells (CLT) showed
approximated a 1.5 fold increase in HO activity, indicating that colchicine also
induced a stress response.
Dwyer, et. ai, reported a 1.9 fold increase in HO activity in rat forebrain
astrocytes after a 20 min. heat stress. They also noted a 7 fold increase in HO activity
after 2 hours of heat stress. In both instances cells were harvested four (4) hours after
a heat stress of 42°C. Ewing, et. ai, (1992) reported a 20 fold increase in HO
activity in rat brain after a 20 minute heat stress at 42°C. Cells in their study were
harvested six (6) hours post treatment. Our data indicates that a typical heat stress
response has occurred, i.e., approximately a doubling in HO activity as a result of
heat stress. In our laboratory, cells were harvested 24 hours after a heat stress of 42°C
for 30 minutes. It is apparent that the extent of the activity may be related to the
severity of the insult (length of time of the stress 15 min, 30 min, 2 hour, etc.) or the
types of tumor cells analyzed (Steels, et. al, 1992).
Our results also indicated that colchicine causes an increase in HO activity in
C-6 glioma. This increase seems to parallel drug resistance; at least there appears to
be some correlation between drug resistance and increased HO activity in cell cultures
at passage #70. This correlation may or may not exist for cell passage #81 since
enzyme activity was not determined in these cells. Our data does show, however, that
cell passage #81 was even more resistant than the colchicine treated cells at cell
passage #70. The correlation between drug resistance and increased HO activity seen
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at cell passage #70 may be a result of the induction of the multiple drug resistance
gene (MDRl) in response to heat shock. Kioka, et. al. (1992) has reported that heat
shock does increase MDRl levels in a drug-resistant mouse tumor cell line.

d. Glutamine Synthetase Activity (GS):
Glutamine synthetase is considered an enzyme marker for astroglia. This C-6
glioma strain often appears to change more towards astroglial character as it ages
(Parker, et. al., 1980). At cell passage #21, Vemadakis,er. al. (1986) noted GS
activity of approximately 1.25 nmol/min/mg of protein for C-6 glioma cells grown
10-14 days in culture. At cell passage #70, used in our study, the GS activity of the
cells was 2.0 ± 0.2 nmol/min/mg protein (Fig. 9). Vemadakis, et. al, (1986) reported
a GS activity at cell passage #82 of approximately 3.7 nmol/min/mg protein in C-6
glioma. The GS activity seen in the unstressed control cells (PNT) at cell passage #70
might be expected as it is intermediate between the older and younger cultures
reported by the Vemadakis group.
The results of our study indicate that GS does not respond to heat stress or
colchicine in the same manner as heme oxygenase. The GS activity in our cell passage
#70 does not appear to have paralleled drug resistance. There are no reports in the
literature to indicate that GS is a heat shock protein inducible by stress. Studies have
shown that various compounds, i.e., glucocorticoids (Pishah and Phillips, 1980),
sodium butyrate (Weingarten, et. al, 1981), ^-adrenergic agonists and dibutyryl
cyclic AMP (Browning and Nicklas, 1982) induce GS activity in C-6 glioma. It may
be that colchicine by itself slightly induces GS activity, while heat stress provides
some uncharacterized additive factor. There was no increase in GS activity in the
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parent strain subsequent to heat stress. Our results did show a significant increase in
GS activity in the heat-shocked colchicine treated cells (CLT + HS), however, no
increase in GS activity was seen in the control cells, and colchicine did not
significantly increase enzyme activity in the absence of heat shock (Fig. 9).

e. Cyclic Nucleotide Phosphohydrolase Activity (CNP):
Colchicine treatment did not appear to change CNP activity (Fig. 10). The
activity in the stressed colchicine treated cells is not different from the control, but it
does respond somewhat to heat stress. There appeared to be a decline (i.e., there was
no increase) in CNP activity when the parent strain was heat stressed. It is uncertain
why the parent strain did not respond to heat stress, but the behavior of CNP is similar
to that seen with GS.
Parker, et. ai, (1980) reported the CNP activity in unstressed C-6 glioma of
cell passage #88 to be 0.125 ± 0.009 umol/min/mg of protein and at cell passage #26
to be 0.688 ± 0.032 umol/min/mg of protein. Results obtained in this laboratory for
CNP activity at cell passage #70 in the control cells (PNT) were 0.207 ± 0.018
umol/min/mg of protein. The CNP activity determined in our control cells may be
decreasing toward the level found by Parker, et. al., at cell passage #88. Based on
Parker's data showing a loss of CNP activity with increased passages, these values
would be expected at our intermediate passage number.
The activities of CNP, an enzyme marker for oligodendrocytes, and glutamine
synthetase, an enzyme marker for astrocytes, were compared. In order to determine
whether our cell line was becoming more astroglial in character (undergoing
transdifferentiation) our data was compared to the results reported by Parker, et. al.,
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for early (21 to 26) and late (82 to 88) C-6 glioma cell passages. The comparison was
undertaken to assess the increase in GS and the decrease in CNP seen with aging
(transdifferentiation); although, we only looked at one point in time. Parker, et. al,
have indicated that since the CNP activity was markedly high and that of GS was low
in the early passages and that this relation was reversed in the late passages; their
findings suggested a transdifferentiation of C-6 glioma cells with passage. At our
passage #70, the GS/CNP ratio in the control cells was approximately 10:1. Parker,
et. al.,'s GS/CNP ratio for cell passages #21-26 was approx. 1.5; 1. At cell passages
#82-86, the GS/CNP ratio was approximately 30:1. The ratio seen after heat stress to
the control cells (PNT + HS) was approximately 11:1. The GS/CNP ratio was
approximately 10:1 in the colchicine treated cells (CLT) and approximately 11:1 in
the heat stressed colchicine treated cells (CLT + HS).Two things are apparent from
our data. One is that the cells that we used have GS/CNP ratios that agree fairly well
with Parker's work. The second point is that neither heat shock nor colchicine did
much to change this ratio.
Colchicine treatment significantly increased heme oxygenase activity and
produced drug resistance. These findings suggest the possibility of using HO as a
marker of drug resistance. Neither GS nor CNP activities appear to parallel the
induction of drug resistance, and these enzymes are not predictive of the onset of drug
resistance.
Objective III: To determine whether the drug resistance seen in the colchicine
treated cells can he reversed by verapamil
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Verapamil presumably acts by inhibiting the activity of the multiple drug
receptor and restoring the cytotoxic activity of drugs like adriamycin, vincristine, and
taxol within the cell (Dalton, et. al, 1989).
Our studies showed that verapamil, in the absence of taxol, appears to have
induced a significant increase in cell counts (approximately 20% over control) when
cells (at passage #81) were pretreated with lOuM verapamil (figure 11). However,
figure 12 shows that even though cells exposed to 10 uM verapamil showed an
increase in cell counts, this concentration still increased the sensitivity of the CLT cell
line to taxol. In addition, the lower concentrations that did not appear to affect cell
counts (1 uM and 5 uM), also reduced the taxol EC50 toward that seen in the control
cells.
Schmidt, et. al, 1988 studied the effects of verapamil by itself on human
medulloblastoma, pinealblastoma, glioma, and neuroblastoma cell lines. They found
that growth rates of these tumor cells were inhibited 10-100% by concentrations of
10-100 uM verapamil. Our results indicate that verapamil by itself, does enhance cell
counts, at least in the colchicine treated cells, at concentrations up to the lowest value
in their study (10 uM).
The fact that the addition of verapamil sensitized our colchicine treated cells
to taxol (decreased cell counts) provides further evidence that colchicine has induced
multiple drug resistance in this glioma cell line. The ability of verapamil to inhibit
the activity of the multiple drug receptor and restore the cytotoxic action of taxol has
previously been documented by Dalton, et. al (1989).

50
In addition, our results show that blocking of the MDR receptor by verapamil
is concentration dependent. Similar findings have been reported by Twentyman, et.
al, 1990 in studies utilizing a panel of multiple drug resistant mouse tumor cell lines.
They studied the relationship between resistance to adriamycin, vincristine,
colchicine, etoposide and resistance modification by verapamil and cyclosporin A
(Table 3). The latter two agents are inhibitors of the multiple drug transporter. When
present in excess, these two inhibitors compete for the multiple drug resistance
receptor, thereby slowing the disappearance of chemotherapeutic agents from resistant
cells.
Twentyman, et. ai, (1990) used concentrations of 3.3 uM and 6.6 uM
verapamil in multiple drug resistant mouse tumor cell lines. They found that the
effect of 3.3 uM verapamil on the MDR cell lines was no greater that that of the
parent line. By comparison, studies in our laboratory showed that 1 uM verapamil
was effective in sensitizing our colchicine treated cells to taxol. Therefore, it appears
that taxol is more effective in our C-6 glioma cell line than in the cell lines studied by
Twentyman, et. al, (1990).
Differences were noted in the taxol EC50 between the colchicine treated cells
(1490 ng/ml at cell passage #70) and the colchicine treated cells—no verapamil
pretreatment (9103 ng/ml at cell passage #81) (figure 13). These differences in EC50
values may be a reflection of the differences in cell passage (passage #70 versus
passage #81) or the differences may reflect the variation in the times which the two
cell passages were harvested. Cell passage #70 was grown to confluence
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(approximately 10 days) prior to harvesting. Cell passage #81 was harvested 48 hours
after the start of verapamil treatment. It is also possible that taxol may be more
effective or have a more substantial affect on cells during the log phase of growth.
Therefore, a direct comparison between the two colchicine treated passages is
difficult.
A comparison of calculated EC50 values (Fig. 13) demonstrated the
effectiveness of verapamil in reversing colchicine induced drug resistance by taxol.
The EC50 of taxol was reduced 14-fold; by exposure to 1 uM verapamil. At 5 uM
verapamil pretreatment, the taxol EC50 was diminished 20-fold. The taxol EC50 was
decreased 125-fold to 72 ng/ml when cells were pretreated with 10 uM verapamil.
This EC50 value of 72 ng/ml is comparable to that found with the control cells (taxol
EC50-

82 ng/ml). This indicates that verapamil at a concentration of 10 uM

completely reversed drug resistance in the colchicine treated cells. Since verapamil is
known to inhibit multiple drug resistance, this evidence supports a MDR mechanism
for the induction of drug resistance to taxol by colchicine in C-6 glioma.

CONCLUSIONS:
(1). Colchicine applied for a 24 hour period at a concentration of 480 ng/ml can
induce drug resistance to taxol in a C-6 glioma cell line
(2). This resistance is characterized by:
a. An increase in the amount of protein per cell.
b. Increased heme oxygenase activity.
c. Of the three enzyme tested, only heme oxygenase correlated well with
drug resistance
(3). Colchicine - induced resistance to taxol is reversed by verapamil and therefore is
likely due to the induction of the multiple drug resistance receptor.
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APPENDIX A
CELL CULTURE
ENZYME ACTIVITY ASSAY
PROTOCOL
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Cell Culture/ Enzyme Activity Assay Protocol
Harvest cells- 0.25% Trypsin (5.0 ml per 75cm^ flask;
1.0 ml per well in 6 well plate; and 0.5 ml per well
in 24 well plate)

Pipet trypsinized cells in X2- X3 volumes
ice cold F-12 media

Cell count(s)
(200ul)
Centrifuge- decant off supernatant
(Earle's balanced salt solution).
approximately 2500 rpm for 5 min.
re-suspend pellet in 5,0 ml EBBS.
1.5 ml Eppendorf tubes as follows :

I
1.0 ml
suspension

SDS-PAGE

1.0 ml
suspension

HO ASSAY

media. Re-suspend in 5.0 ml EBBS
Vortex briefly; centrifuge at
Repeat procedure. Finally,
Pipet solution into prelabeled

1.0ml
suspension

BRADFORD
PROTEIN

I
1.0 ml
suspension

GS ASSAY

I
1.0ml
suspension

CNP ASSAY

Centrifuge tubes on high setting in Beckman Microfuge for approximately 3 0
seconds. Decant off supernatant. Re-suspend cells in appropriate volume
of buffer as follows

SDS-PAGE

lOOul
pH 7 4 Harvest buffer
0.25M Sucrose,20mM
Tris HCL

HO ASSAY

PROTEIN ASSAY

200ul
pH 7.4 Microsomal
buffer;0 IM Pot
Phosphate,
20% glycerol
ImM EDTA

GS ASSAY

150ul
pH 7.3 PBS

CNP ASSAY

800ul
PBS : Imidazole
buffer

200ul
0 32M crose

QUICK-FREEZE each tube ASAP in liquid nitrogen or dry-ice acetone or
isopropanol bath.
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CELL COUNTING PROCEDURE

Reagents :
Trypan Blue- 0.4% in 0.85% saline
0.85% sodium chloride (saline)
Trypsinized cell suspension in cold F-12 media
Instruments :
Hemacytometer
Fisher model
Olympus model M021 stereomicroscope
200-1000ul variable volumetric pipettor and tips
Procedure:
1). Into pre-labelled culture tubes the following solutions
were pipetted:
a. SOOul trypan blue dye
b. SOOul 0.85% saline
c. 200ul cell suspension in F-12 media
2).

Each tube was vortexed briefly.

3).

Using a pasteur pipet transfer sufficient enough volume
of cell suspension to fill each grid in a hemacytometer
by capillary action.

4) .

All of the cells in each of the four corner and center
grids were counted for each sample.

5). To obtain the average cell number, the total number of
cells
counted was divided by the number of grids
counted.
6) .

This number was multiplied by 5 to correct for the
dilution factor.

7) .

To obtain the number of cells per milliter in the
original solution, the number obtained in step 6
above was multiplied by 10*.
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BRADFORD PROTEIN ASSAY PROCEDURE

Reagents :
Phosphate buffered saline: pH 7.3
O.OIM
NaOH solution: 0.05N
HCL solution:
1.21N
Bovine serum albumin protein standards: 15,3 0,5 0 mg/dl in
saline.
Cell homogenate: suspended in phosphate buffered saline.
Protein assay solution: Prepared by mixing 1 volume of
protein dye reagent with 9 volumes deionized water in a
plastic container.
Instruments :
80 °C water bath
0-4°C ice bath
Bausch Sc Lomb spectronic 2 0
Eppendorf variable volumetric pipettors with disposable
tips
vortex mixer
Procedure :
1). 0.1 ml each of protein standards, samples, and
distilled
water as a blank were hydrolyzed in
tubes containing 600
ul 0.05N NaOH by heating at
80°C for lOmin.
2). After heating the tubes were immediately placed in an
ice bath for 5 min.
3). The solutions were then neutralized with 1 drop
(approx
50ul) of 1.21N HCL.
4). 50ul each of the previously hydrolyzed standards,
samples
and blank were pipeted into tubes containing 2.5ml
protein assay solution.
5). Each tube was mixed thoroughly by vortexing briefly.
6). The tubes were equilibrated at room temperature for
3min. prior to transferring to a cuvette.
7). The absorbance [O.D.] of the standards and samples
vs the blank were measured at 5 95nm.
8). The amount of protein in each sample was estimated
from the slope of the regressed line in which the
absorbance [O.D.] was plotted against the
concentration
(mg/ml) of the protein standards.
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HEME OXYGENASE ASSAY

Reagents:
Potassium phosphate buffer: 0.IM K2HPO4, pH 7.4
Deferroxamine: lOOmM stock solution, 65.7mg in 1.0ml
K2HPO4 buffer
Bovine serum albumin: ImM stock solution, 66.0mg in 1.0ml
K2HPO4 buffer
Hemin (Hemin chloride): ImM stock solution, 6.5mg in 0.IM
K2HPO4 buffer:0.IN NaOH (9.5:0.5)
^-Nicotinamide adenine dinucleotide phosphate ((8-NADPH) :
lOOmM stock solution, 74.3mg in 1.0ml 0.IM K2HPO4
buffer
Bilirubin: ImM stock solution, 5.85mg in 10ml O.IM K2HPO4 :
O.IN NaOH (9.5:0.5)
Biliverdin: ImM stock solution, 5.82mg in 10ml O.IM
K2HPO4:0 . IN NaOH (9.5:0.5)
Cell homogenate buffer: O.IM K2HPO4, 20% (v/v) glycerol,
ImM EDTA, pH 7.4
C-6 glioma cell homogenate: previously prepared and frozen
(see cell culture/ enzyme activity protocol)
Rat liver cytosol: previously prepared and frozen, source
of biliverdin reductase.
Instruments :
37°C water bath
Gilford Stasar III spectrophotomer with temperature
controlled flow through cuvette
Conical shaped teflon cell homogenizer and drill
Procedure:
1). Cell suspension(s) and one milliter of rat cytosolic
fraction were removed from -20°C freezer and allowed to
thaw.
2). The cell suspension was homogenzed using a teflon
homogenizer.
3). Into 12 X 75mm culture tubes the following reaction
mixtures were pipeted:
Reactant

Amount of Stock Solution to pipet

5mM Deferroxamine
2 5uM Hemin
15uM Bovine serum albumin
*lmM NADPH
C-6 glioma cell homogenate
Rat cytosolic fraction
O.IM K2HPO4 buffer
*Note: (see step 4 below)

50 ul
25 ul
15 ul
10 ul
200ul
50 ul
650ul
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4). The reaction mixture was preheated without NADPH at 37°C
for 5 min.
5). 10 ul NADPH was added and the mixture was gently
vortexed and then aspirated into the spectrophotometer.
6). The absorbance (AO.D.) was measured at 1 min. and again
at 15 min. at a wavelength setting of 453nm.
7). The Heme oxygenase activity (nM/min) was estimated by
multiplying the rate of change in absorbance (AO.D./min)
by the inverse of the slope of the regression line in
which absorbance (O.D.) was plotted against bilirubin
standards(nM):
AO.D./min x nM/O.D.(inverse slope)= nM/min
8). After correction for the total amount of protein in the
original sample volume, Heme oxygenase activity was
expressed as
pmol/min/mg protein
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GLUTAMINE SYNTHETASE ASSAY

Reagents :
Lysis buffer: lOmM Imidazol HCL, 0.5mM EDTA, pH 7.0 with
HCL
Imidazol-HCL: IM, pH 7.2 with HCL
L-glutamine: 0.25M in distilled HjO
Manganese chloride: 4mM in distilled HgO
Hydroxylamine : 1.25M in distilled H^O, make fresh each
time
Sodium Arsenate: 200mM in distilled HgO
Adenosine 5'Diphosphate (ADP): 8mM in distilled HjO
Ferric chloride: 0.37M FeCLj, 0.67M HCL, 0.20M
trichloroacetic acid
Gamma-glutamyl-hydroxymate (L-glutamic acid gammamonohydroxymate): 5mM in PBS/lysis buffer
Phosphate buffered saline; O.OIM, pH 7.30
Previously prepared and frozen aliquot of C-6 glioma cells
(see cell culture/ enzyme activity assay protocol)
Instruments :
0-4°C ice bath
37°C water bath
Teflon tissue homogenizer & drill
Bausch & Lomb Spectronic 2 0 spectrophotometer
Damon lEC HN-S Centrifuge
Vortex
Procedure:
1). Frozen cell suspensions were thawed and homogenzed in
PBS/lysis buffer (1:1).
2). Tubes were labelled in triplicate for samples,
standards, and blanks.
Standard
tunoles gamma-6H

0

Vol. of 5mM
soin.
to add
(.005uM/ul)

Vol. of
PBS/lysis
buffer (ul)

Oui

250ul

. 02

4

246

. 05

10

240

.10

20

230

.20

40

210

.30

60

190

.40

80

170
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3). To each of the blanks, 250ul of PBS/lysis buffer (1:1)
was added.
4). The standard curve was set up as follows:
5). To the sample tubes, 250ul of cell homogenates were
added.
6). The reaction mixture was prepared as follows:

for 40 tubes

for 60 tubes

L-glutéunine

4 . 0ml

6 . 0ml

Imidazole

2 . 0ml

3 . 0ml

ADP

1. 0ml

1. 5ml

MnCLj

1. 0ml

1.5ml

Hydroxy1amin

1. 0ml

1. 5ml

NaAs

1. 0ml

1.5ml

7). 25Oui of the reaction mixture was added to each tube;
blanks, standards, and samples.
8). Each tube was vortexed briefly and then placed in a 37°C
water bath for 3 0 minutes.
9). After the 3 0 minute incubation period the tubes were
placed in an ice bath.
10) 0.5ml FeCLj solution was added to each tube, vortexed
and then centrifuged at approx. 2000rpm for 5 minutes.
11).The FeCLj solution containing the gamma-glutamylhydroxymate (yGHjwas measured spectrophotometrically at
555nm.
12) .The absorbance (O.D.) of the FeCL^ solution for each of
the standards and samples were recorded and corrected
for the absorbance of the blanks.
13).The 7-glutamyl hydroxymate activity (uM/min) was
estimated by multiplying the rate of change in
absorbance (AO.D./min) by the inverse of the slope of
the regressed line in which absorbance (O.D.) was
plotted against varying concentrations(umoles) of y glutamyl hydroxymate:
AO.D./min x uM/O.D. (inverse slope)= umol/min
14).After correction for the total amount of the protein in
the original sample volume (800ul), the y-glutamyl
hydroxymate was expressed as umol/min/mg protein.
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2',3'-CYCLIC NUCLEOTIDE 3'-PHOSPHOHYDROLASE (CNP) ASSAY

Reagents :
Sucrose; 0.32M in distilled HjO
Tris-HCL: 0.20M, pH to 7.5
Sodium Deoxycholate: 1% solution in distilled HjO
Tris-maleate : 50tnM, pH to 6.2
Tris-HCL: 0.3 0M containing 21mM MgCLj, pH 9.0
2',3'-cAMP: 7.5mM, in Tris-maleate buffer. Made fresh the
day of the assay
Alkaline phosphatase: approximately 0.7 alkaline
phosphatase units/ lOOul of 0.30M Tris-HCL containing 21mM
MgCLj
Isobutanol/Benzene: (1:1) mix equal parts of these
reagents
Ammonium molybdate: 1.5% in 0.5N HgSO^
H2SO4 solution: 0. 5N
Instruments :
Teflon tissue homogenizer
90°C water bath
30°C water bath
Bausch & Lomb Spectronic 2 0 spectrophotometer
0-4°C ice bath
C-6 glioma cell suspension, previously isolated and frozen
(see cell culture/ enzyme activity assay protocol)
Beckman Microfuge B
Procedure :
1). Previously frozen aliquots of cell suspensions were
thawed and then centrifuged at high speed for 6 0 seconds
in a Beckman microfuge.
2). The supernatant was discarded and the resulting pellet
was homogenized in 200ul 0.32M sucrose.
3). lOOul 0.2M Tris-HCL, pH 7.5 and 200ul 1% Na deoxycholate
was added to the homogenate.
4). The homogenates were placed in an ice bath for 10
minutes.
5). 150ul of distilled water was added to each and then the
samples were re-homogenized.
6). Using 5ml conical tubes, three blanks were set up by
adding 180ul 50mM Tris-maleate, pH 6.2 to each of the
tubes.
7) . Samples were set upin triplicate by adding 13Oui 50mM
Tris-maleate,pH 6.2 and 50ul homogenate to the
appropriate number of tubes.
8). 20ul of substrate (7.5mM 2',3'-cAMP) was pipetted into
each tube. Each tube was then briefly vortexed.
9). The tubes were then placed in a 30°C shaking water bath
for 20 minutes.
10).After incubation the tubes were first, plunged into a
90°C water bath for 1 minute and then, returned to the
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30°C water bath for 5 minutes to cool down.
11).A standard curve for 2'-AMP was set up as follows:
Standard
uMoles 2'-AMP

Vol. of 5mM 2'AMP
(0.005uM/ul)

Vol. of Trismaleate
buffer,pH 6.2
(ul)

0

0

200

0.025

5

195

0 . 050

10

190

0 . 100

20

180

0 .200

40

160

0.250

50

150

0.300

60

140

0 .400

80

120

0 .500

100

100

0 . 750

150

50

1 . 000

200

0

12). lOOul of alkaline phosphatase was added to each tube.
13). Each tube was vortexed briefly, and then placed in a
30 'C water bath for 2 0 minutes.
14). After incubation 1.5ml of isobutanol/benzene (1:1) and
1.5ml of 1.5% ammonium molybdate was added to each
tube.
15). Each tube was vortexed for approx. 20 seconds and then
centrifuged for 5 min. at 2000rpm.
16). Color production was measured spectrophotometrically at
410nm.
17). The 2',3'-CNP activity (uM/min) was estimated by
multiplying the rate of change in
absorbance(AO.D./min.) by the inverse of the slope of
the regressed line in which absorbance (O.D.) was
plotted against varying concentrations (umoles) of 2'AMP standard:
AO.D./min x umol/O.D. (inverse slope)=
umol/min.
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18). After correction for the total amount of protein in the
original volume (650ul), the 2',3'-CNP activity was
expressed as umol/min/mg protein.
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RAT LIVER CYTOSOL FRACTION

Reagents:
Sodium chloride: 0.15M in distilled water
Tissue buffer: 0.25M sucrose, 20mM Tris-HCL, pH7.4
Instruments :
Refrigerated centrifuge
Brinkman LJ-65 ultra-centrifuge
Potter-Elvehjem tissue homogenizer
Procedure :
All preparative steps were performed at 4°C or on ice
1). Livers from Sprague-Dawley rats were soaked in
approximately 50ml cold 0.15M NaCL.
2). Approximately lOgms of diced liver was homogenized in a
Potter-Elvehjem homogenizer in 4 vol. tissue buffer,
pH7.4.
3). The homogenate was then centrifuged at 5,000g for lOmin.
4). The 5,000g supernatant fraction was then ultracentrifuged at 24,000 rpm for 1 hour.
5) . The resultant supernatant cytosolic fraction was then
divided into 1.0ml aliquots and immediately frozen in
liquid Ng until needed for the assay procedure.
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SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS
(SDS-PAGE)

Reagents :
Stock solution: 30% Acrylamide:0.8% N,N-Methylene bis
acylamide (Bis)
Trisma base
Tris Running buffer: 1.875M, pH 8.8
HCL solution: concentrated
Tris Stacking buffer: l.OM, pH 6.8
Ethylenediamine tetraacetic acid (EDTA): 0.2M in distilled
HzO
N,N,N',N'-tetramethylene amine: TEMED, neat
Ammonium persulfate: 10% in distilled HgO
Running buffer: pH 8.3, Sigma 7-9 Tris, glycine. Sodium
dodecyl sulfate (SDS)
Solubilizing solution: 2x, 10% SDS, 2 ^-mercaptoehtanol,
glycerol, IM tris (pH 6.8), distilled HgO,
Bromophenol blue
Fixer/Destainer: 50% methanol, 7% glacial acetic acid, 43%
distilled water
Stain: Coomassie Brilliant Blue R, 0.25% in
fixer/destainer
Previously prepared and frozen aliquot(s) of C-6 glioma
cells
(see cell culture/ enzyme activity assay protocol)
Commercially prepared SDS-PAGE molecular weight markers
Instruments:
Extech Model 671 pH Meter
Lab Line magnetec stirrer
100"C Oven
Hoefer Scientific SE600 Vertical Slab Gel Electrophoresis
Unit
E-C Model EC60 0 Power Supply
Mettler Model 1200 Balance
5 Oui Syringe
Procedure :
A. Preparation of the Separating Gel
1). The SE6 00 Vertical Slab Gel Unit was assembled in the
casting mode using 1.0mm spacers.
2). A 12.5% Separating gel was prepared by pipeting the
following solutions, in order, into a 12 5ml Erlenmeyer
flask :
a) Acrylamide: BIS (30gm:0.8gm)
12.5ml
b) 1.875M tris, pH 8.8
6.0ml
c) 0.2M EDTA
0.3ml
d) distilled HgO
10.9ml
e) TEMED
.015ml
f) 10% NH4 persulfate
0.3ml
3). The solution was immediately pipeted into the sandwiches
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to a level about 4.0cm from the top.
4). The gel was overlayed gently with approximately 0.3ml
distilled water.
5). The solution was allowed to polymerize for 20-30
minutes.
6). After 30 minutes the overlay was poured off and excess
water removed with Whatman no. 1 filter paper.
B. Preparation of the Stacking Gel
1). The Stacking Gel was prepared by pipeting the following
solutions, in order, into a 125ml Erlenmeyer flask:
a) Acrylamide: BIS (30gm:0.8gm)
2.5ml
b) l.OM tris, pH 6.8
1.9ml
c) 0.2M EDTA
0.15ml
d) distilled HgO
10.3ml
e) TEMED
7.5ul
f) 10% NH4 persulfate
0.15ml
2). The 1.0mm spacer comb was inserted into the sandwich.
3) . The Stacking gel was gently pipeted into the sandwich
taking care to remove all air bubbles from around the
spacer.
4). The Stacking Gel was allowed to polymerize for 20-30
minutes.
C. Preparation of Cell Homogenate
1). Equal volumes of cell homogenate and 2X Solubilizing
Solution
were combined in a test tube.
2). The tube was placed in a boiling water bath for
approximately 90 seconds to denature the proteins with
SDS.
D. Loading and running the Gels
1) . The comb(s) were gently removed from the gels.
2). Each well was rinsed with Running buffer.
3). Using a 50ul syringe the sample(s) (cell homogenates
equivalent to 10-20ug protein) and the standard
molecular weight markers were underlayed in the
appropriate
well.
4). The Gel Sandwiches were then assembled into the buffer
chamber, according to manufacture specifications, and
the appropriate volume of Running Buffer, pH 8.3 added.
5). The lid was placed on the unit and the unit connected to
the power supply. The power supply was run at a constant
current of 50 mA
6) . The gels were electrophoresed with constant cooling and
stirring until the marker dye had reached the bottom of
plate.
E. Staining and Destaining the Gels
1). After disassembling the gels from the sandwiches, the
gels were fixed in Fixer/Destainer solution for 4 hours
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on a rotary shaker.
2). The proteins in the gel were visualized by staining with
the Coomassie Blue staining solution for 30 minutes and
then repeatedly destaining with Fixer/Destainer
solution.
3). The position of the Heat shock proteins- hsp 32, 70, &
90 were compared by visual comparison to the known
molecular weight markers.

